Compare Repligen Corporation Common Stock (RGEN) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Energy Select Sector SPDR Fund — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Energy Select Sector SPDR Fund trades at $68.02 (market cap $42.98B). The key difference: Energy Select Sector SPDR Fund is far larger — about 3.9× Repligen Corporation Common Stock's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Energy Select Sector SPDR Fund for 68 Days on average.
| RGEN | XLE | |
|---|---|---|
Market Cap | $11.14B | $42.98B |
Volume | 1,259,263 | 27,490,546 |
Sector | Health | — |
52-Week High | $194.57 | $67.61 |
52-Week Low | $102.87 | $42.64 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XLE trades at $67.17, up 1.74% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF's performance is closely tied to oil price dynamics, with recent news highlighting supply disruptions and geopolitical tensions supporting energy sector strength. Key support lies near $65, while resistance is seen around $67.
Outlook remains positive near-term due to oil market tightness, but risks include potential price reversals and sector volatility. Investors should weigh the ETF's concentrated oil and gas exposure against broader energy infrastructure alternatives for diversified income and stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
